Abeona Therapeutics (ABEO) Announces DSMB Approval of ABO-102 Dose Escalation in Phase 1/2 Second Cohort for Sanfilippo Syndrome Type A
Tweet Send to a Friend
Abeona Therapeutics Inc. (Nasdaq: ABEO) announced that the Data Safety Monitoring Board (DSMB), an independent group of medical experts closely ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
